Click to enlarge video or view it below.

The Wyss Institute has developed a targeted vascular nanotherapeutic (Vascular NanoRx) platform that targets drugs to stenotic (narrowed) sites in blood vessels to treat life-threatening and debilitating clotting disorders, such as stroke, pulmonary embolism, acute coronary syndrome (myocardial infarction, unstable angina), thrombosed hemodialysis access sites, and potentially atherosclerosis. The platelet-sized Vascular NanoRx microaggregates (large blue aggregates) disperse into drug-carrying nanoparticles (blue dots) when exposed to high shear stress caused by a clot that narrows a blood vessel, resulting in a concentration of drug-coated nanoparticles at the site of the stenosis.